AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Sarepta Therapeutics Enters Settlement Agreement to Resolve Patent Infringement Litigations
On September 23, 2026, Sarepta Therapeutics, Inc. and its affiliates entered into a settlement agreement with REGENXBIO Inc., UPenn, and Catalent, resolving pending patent infringement litigations and appeals related to U.S. Patents. This agreement addresses issues surrounding patents U.S
Company Information
Company
Sarepta Therapeutics
Location
Cambridge, Massachusetts, United States
About
Sarepta Therapeutics, Inc. is the leader in precision genetic medicine for rare diseases, with a focus on Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs). The company is on a mission to engineer life-changing therapies for patients and has a multi-platform Precision Genetic Medicine Engine driving its vast pipeline.
CambridgeBiotechnologyHealthcareHealth CareTherapeutics